Citius Pharmaceuticals (CTXR) Share-based Compensation (2014 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Share-based Compensation came in at $3.8 million in Q1 2026, up 40.2% YoY from $2.7 million in Q1 2025, and down 11.49% on a QoQ basis from $4.3 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Share-based Compensation (2014 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 13 years of Share-based Compensation data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Share-based Compensation rose 40.2% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 2341.25% YoY) and the FY2025 annual result came in at $10.8 million, up 3713.23% from the prior year.
- Share-based Compensation slipped to $3.8 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.3 million in Q4 2025 to a low of -$8.9 million in Q3 2024.
- A 5-year average of $1.4 million and a median of $2.5 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 3215.77% in 2024, down 389.8% in 2024.
- Tracing CTXR's Share-based Compensation over 5 years: stood at $1.2 million in 2022, then slumped by 93.66% to $76146.0 in 2023, then soared by 3215.77% to $2.5 million in 2024, then soared by 69.53% to $4.3 million in 2025, then declined by 11.49% to $3.8 million in 2026.
- The last three Share-based Compensation figures came in at $3.8 million (Q1 2026), $4.3 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.79 Mn |
| Mar 31, 2026 | 3.79 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Sep 30, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 3.06 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | -8.91 Mn |
| Sep 30, 2024 | -8.91 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Mar 31, 2024 | 3.08 Mn |
| Dec 31, 2023 | 76,146.00 |
| Dec 31, 2023 | 76,146.00 |